PhosImmune, Agenus deal

Agenus acquired cancer vaccine company PhosImmune for $2.5 million in cash up front and $7.4 million in shares of Agenus common stock. PhosImmune shareholders are also eligible for up to $35 million in milestones, payable in cash or Agenus stock. ...